{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-067814","form_type":"8-K","ticker":"ACOG","cik":"0001655923","company_name":"Alpha Cognition Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.992747+00:00","generated_at":"2026-05-31T09:44:31.792997+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alpha Cognition Q2 net loss $2.1M; FDA approves ZUNVEYL for Alzheimer's","bullets":["Q2 2024 net loss $2.1M ($0.01/share) vs Q2 2023 net loss $2.8M ($0.03/share).","Cash and equivalents $1.0M at June 30, 2024; no revenue reported.","R&D expenses $0.9M in Q2, down from $1.3M YoY on trial completion.","FDA approved ZUNVEYL (benzgalantamine) for mild-to-moderate Alzheimer's disease.","G&A expenses rose to $1.2M in Q2, including $2.3M shares for services under Spartan Capital agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-067814","json":"https://secwatch.observer/filing/0001213900-24-067814.json","markdown":"https://secwatch.observer/filing/0001213900-24-067814.md","text":"https://secwatch.observer/filing/0001213900-24-067814.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655923/000121390024067814/0001213900-24-067814-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655923/000121390024067814/ea0211011-8k_alpha.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:44:31.792997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}